Ilya Petrou, MD


Glaucoma: Hyperemia a common cause for medication changes

Hyperemia is one of the main reasons why patients with glaucoma do not adhere to or persist with their topical therapeutic regimen. Patients end up switching to another possibly more tolerable medication, and the changing of medications has significant financial implications. Latanoprost has the lowest incidence of hyperemia among the prostaglandin analogs. Patient adherence is crucial in a chronic progressive disease such as glaucoma, where non-adherence can lead to visual loss and decline in quality of life, creating societal health and economic burdens.

Brimonidine/timolol controls IOP in clinical setting

Brimonidine 0.2%/timolol 0.5% fixed-combination ophthalmic solution effectively lowers and controls IOP and is likely to be associated with increased patient adherence to therapy and decreased unwanted side effects such as ocular irritation, according to one ophthalmologist.

Low IOP is measured with great accuracy using non-contact applanation tonometer

A non-contact applanation tonometer (Ocular Response Analyzer, Reichert) appears to be more effective than the Goldmann applanation tonometer (GAT) in assessing very low and negative IOP values using the non-contact applanation tonometer's corneal-compensated IOP (IOPcc) parameter. The GAT may be the long-accepted gold standard, but the more accurate assessment of IOP using the non-contact applanation tonometer challenges this gold standard and raises questions as to which of the two techniques is optimal in measuring IOP.

Oral fenretinide may slow, halt geographic atrophy in those with age-related macular degeneration

August 01, 2009

Oral fenretinide given once daily may slow the progression of geographic atrophy in patients with age-related macular degeneration, according to an interim analysis.

Spectral-domain optical coherence tomography has practical applications in the diagnosis, management of retinal disease

February 01, 2009

Spectral-domain optical coherence tomography is becoming an invaluable diagnostic tool and greatly helps ophthalmologists better manage their patients' conditions, according to one expert. This improved management of conditions, he said, can be realized not only in the medical arena but also in the surgical arena as well.

Induction-maintenance therapy shows promise for neovascular age related macular degeneration treatment

February 01, 2009

Employing a therapeutic approach consisting of pan-vascular endothelial growth factor (VEGF) blockers such as ranibizumab (Lucentis, Genentech) and/or bevacizumab (Avastin, Genentech) as an induction therapy, followed by a selective VEGF blocker such as pegaptanib (Macugen, OSI/Eyetech) as a maintenance therapy, appears to be effective in patients with neovascular age-related macular degeneration, according to the interim results of the LEVEL study. This approach may be preferred for many patients from the standpoint of systemic safety.